Investing.com -- Immuneering Corp (NASDAQ:IMRX) stock surged 21.7% Monday after the clinical-stage oncology company announced ...

S&P forecasts that Metsa Board’s adjusted EBITDA in 2025 will drop to €65 million-€75 million, down from €163 million in 2024 and well below the previous forecast of €212 million.

Investing.com -- Fitch Ratings has upgraded Newmark ’s commercial primary servicer rating to ’CPS2+’ from ’CPS2’ while affirming its commercial special servicer rating at ’CSS3+’, the rating agency ...

The negative outlook reflects Moody’s expectation that Wesco’s debt-to-EBITDA ratio will remain elevated, with revenue projected to decline in the low single digits in 2025 due to weakness in the ...